These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 915355)

  • 1. Endocrine therapy and serum and urinary testosterone levels, as a monitoring, in patients with carcinoma of the prostate.
    Oka M; Nakashima K
    Nihon Gan Chiryo Gakkai Shi; 1977 Sep; 12(3):336-42. PubMed ID: 915355
    [No Abstract]   [Full Text] [Related]  

  • 2. [Urinary 17-ketosteroid excretion and serum 17-hydroxycorticosteroid levels during treatment of prostate cancer patients].
    Portnoĭ AS; Parfent'eva LN
    Vopr Onkol; 1969; 15(12):30-4. PubMed ID: 5372969
    [No Abstract]   [Full Text] [Related]  

  • 3. [Hormonal changes in carcinoma of the prostate].
    Rodrigues-Netto Júnior N; Da Silva RP; Hernández AJ
    Rev Paul Med; 1979; 94(1-2):24-6. PubMed ID: 120973
    [No Abstract]   [Full Text] [Related]  

  • 4. Carcinoma of the prostate: early endocrine therapy is best.
    Spirnak JP; Resnick MI
    Semin Urol; 1983 Nov; 1(4):269-79. PubMed ID: 6399613
    [No Abstract]   [Full Text] [Related]  

  • 5. [Orchidectomy and oestrogen therapy of carcinoma of the prostate (author's transl)].
    Straube W; Braun JS
    Urologe A; 1974 Jul; 13(4 Pt A):198-201. PubMed ID: 4137442
    [No Abstract]   [Full Text] [Related]  

  • 6. [Endocrine therapy in late cancer of the prostate].
    Momose G
    Nihon Naibunpi Gakkai Zasshi; 1965 Dec; 41(9):1069-71. PubMed ID: 5895676
    [No Abstract]   [Full Text] [Related]  

  • 7. Urinary oxalate excretion during anti-androgenic therapy.
    Tiselius HG; Varenhorst E; Carlström K; Larsson L
    Invest Urol; 1980 Sep; 18(2):110-1. PubMed ID: 6447675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Endocrine therapy for prostatic carcinoma--the clinical trial to compare the efficacy of LH-RH analogue, ICI 118630 (Zoladex) with castration or estrogen].
    Usami M; Kotake T; Matsuda M; Okajima E; Osafune M; Akaza H; Niijima T; Aso Y; Araki T; Itatani H
    Hinyokika Kiyo; 1988 Oct; 34(10):1853-63. PubMed ID: 2977527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Serum testosterone level in patients with advanced prostatic cancer during androgen suppressive treatment].
    Fosså SD; Høst H; Aakvaag A
    Tidsskr Nor Laegeforen; 1981 Oct; 101(28):1570-3. PubMed ID: 7339933
    [No Abstract]   [Full Text] [Related]  

  • 10. Serum sex hormone binding globulin and testosterone binding after estradiol administration, castration, and their combination in men with prostatic carcinoma.
    Leinonen P; Hammond GL; Lukkarinen O; Vihko R
    Invest Urol; 1979 Jul; 17(1):24-7. PubMed ID: 571863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term effects of endocrine treatment on serum steroids in advanced prostatic carcinoma patients.
    Lukkarinen O; Hammond GL; Kontturi M; Vihko R
    Invest Urol; 1980 Jan; 17(4):328-31. PubMed ID: 6444293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hormonal consequences of orchidectomy for carcinoma of the prostate. With special reference to the measurement of free testosterone in saliva and prostatic dihydrotestosterone levels.
    Boccon-Gibod L; Laudat MH; Guiban D; Steg A
    Eur Urol; 1988; 15(1-2):99-102. PubMed ID: 3215246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.
    Morote J; Orsola A; Planas J; Trilla E; Raventós CX; Cecchini L; Catalán R
    J Urol; 2007 Oct; 178(4 Pt 1):1290-5. PubMed ID: 17698136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Principles for the conservative drug therapy treatment of prostate cancer].
    Hofmann W
    Z Urol Nephrol; 1981 Sep; 74(9):697-704. PubMed ID: 7314992
    [No Abstract]   [Full Text] [Related]  

  • 15. [Therapy of prostatic carcinoma].
    Kopper B; Lyding R
    Dtsch Med Wochenschr; 1977 Oct; 102(40):1423-6. PubMed ID: 71981
    [No Abstract]   [Full Text] [Related]  

  • 16. The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer.
    Nishiyama T; Hashimoto Y; Takahashi K
    Clin Cancer Res; 2004 Nov; 10(21):7121-6. PubMed ID: 15534082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of prostatic carcinoma from the endocrinologic viewpoint].
    Rothauge CF; Wildberger JE; Szasz G; Graef V
    Urologe; 1969; 8(5):237-9. PubMed ID: 5359388
    [No Abstract]   [Full Text] [Related]  

  • 18. [Fibrinolysis in prostate carcinomas of varying grades of differentiation with respect to estrogen therapy and castration].
    Oehler D; Feustel A
    Z Urol Nephrol; 1980 Mar; 73(3):201-10. PubMed ID: 7434984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostatic cancer: endocrine treatment.
    Chisholm GD
    Turk J Pediatr; 1984; 26(1-4):273-6. PubMed ID: 6537080
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of orchiectomy and various doses of stilbestrol on plasma testosterone levels in patients with carcinoma of the prostate.
    Mackler MA; Liberti JP; Smith MJ; Prout GR
    Surg Forum; 1970; 21():540-1. PubMed ID: 5535268
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.